: MM

REFERENCES
1. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein
thrombosis in the general population: systematic review. Eur J Vasc
Endovasc Surg 2003;25:1-5.
2. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP,
Van Der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared
with subcutaneous low-molecular-weight heparin administered at
home. The Tasman Study Group. N Engl J Med 1996;334:682-7.
3. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A
comparison of low-molecular-weight heparin administered primarily
at home with unfractionated heparin administered in the hospital for
proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
4. BÃ¼ller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F,
et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med
2004;140:867-73.
5. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A
meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining
some unanswered questions regarding location of treatment, product
type, and dosing frequency. Arch Intern Med 2000;160:181-8.
6. Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location
of thrombosis determine the risk of disease recurrence in patients with
proximal deep vein thrombosis? Am J Med 2001;110:515-9.
7. Prandoni P, Villalta S, Bagatella P, Rossi L,